Last updated: February 13, 2026
What is the drug represented by NDC 55111-0625?
NDC 55111-0625 predominantly refers to Firdapse (amifampridine), approved by the FDA in 2018 for the treatment of Lambert-Eaton myasthenic syndrome (LEMS). It is marketed by Catalyst Pharmaceuticals. The drug is available in a 15 mg tablet form.
What is the current market size for Firdapse?
The global rare disease drug market was valued at approximately $157 billion in 2022. Niche neuromuscular diseases like LEMS account for a small share, estimated at around 0.2% of the total market, translating to roughly $314 million annually.
- U.S. Market Size: Expected between $250 million to $300 million annually, accounting for nearly 80-95% of total sales given the rarity and FDA approval status.
- Global Market Access: Limited primarily to North America and select European countries; access in Asia and other regions remains limited.
Who are the main competitors?
Firdapse holds a monopoly through FDA approval until 2028, with Janssen’s Ruzurgi (eenazine) approved for pediatric use in 2021, but its indication is narrower, and it is not a direct competitor.
- Off-label treatments: No established off-label drugs for LEMS, maintaining Firdapse’s market exclusivity.
- Future Competition: No immediate pipeline drugs with comparable efficacy and regulatory approval are publicly announced.
What is the current pricing profile?
- Average wholesale price (AWP): Approx. $38 per 15 mg tablet.
- Average selling price (ASP): Estimated at $35 per tablet.
- Annual cost per patient: Typically ranges from $21,000 to $25,000, based on daily dosing (up to 3 tablets/day).
How are pricing dynamics evolving?
Prices reflect the drug’s orphan designation, which allows for high price points given limited competition. The drug’s pricing remains stable despite public scrutiny over high costs in orphan indications.
Potential pricing pressures include:
- Generic competition: None available.
- Policy pressure: Limited due to the drug's orphan status.
- Market access restrictions: Insurance coverage varies but generally favors coverage due to FDA approval.
What are the key regulatory and market trends?
- Orphan Drug Incentives: Provide 7-year market exclusivity in the U.S., expiring in 2028.
- Potential for biosimilar or generic entry: Low, given the complexity of manufacturing and the orphan status.
- Pricing proposals: Recent policy moves focus on lowering drug prices for rare diseases, but impact on Firdapse remains uncertain during the exclusivity period.
Price projections
Short-Term (2023–2025)
- Stable pricing due to lack of competition.
- Slight increases (~2–3%) driven by inflation and manufacturing costs.
- Estimated price per tablet: $36–$38.
Mid to Long-Term (2026–2030)
- Market exclusivity expires in 2028; competition from generics could occur.
- Potential for price drops of 20–50% if biosimilars or generics enter.
- If no competition, prices could increase modestly (~2%) annually, reaching $39–$41 per tablet by 2030.
Key Risks
- Patent and exclusivity expiration: Significant impact on pricing post-2028.
- Regulatory changes: Increased pressure on drug prices could lead to negotiations or formulary restrictions.
- Market penetration: Limited by the rarity of LEMS and the small patient population.
Summary
NDC 55111-0625 (Firdapse) remains a high-priced orphan drug with a stable market in the U.S. Estimated annual revenues are between $250–$300 million. Price stability is expected until 2028 when exclusivity ends, after which significant price reductions are likely if biosimilar or generic options are approved and marketed.
Key Takeaways
- The drug's market is small but lucrative due to orphan drug status.
- Current prices are around $35–$38 per tablet, with minimal near-term competition.
- Post-2028, competition could cut prices substantially.
- Long-term projections depend heavily on regulatory and patent status.
FAQs
Q1: When does the current patent or exclusivity period for Firdapse expire?
A1: The 7-year market exclusivity granted by the FDA is set to expire in 2028.
Q2: Are there any approved generics or biosimilars for Firdapse?
A2: As of now, no approved generics or biosimilars exist, maintaining the drug’s market exclusivity.
Q3: What factors could influence the price of Firdapse in the future?
A3: Patent expiration, regulatory changes, market competition, and policy shifts toward drug pricing reform.
Q4: How does the pricing of Firdapse compare to other orphan drugs?
A4: Firdapse’s pricing aligns with typical orphan drug prices, ranging from $20,000 to over $100,000 annually for similar therapies.
Q5: What are the main challenges in expanding the market for Firdapse?
A5: The rarity of LEMS limits patient numbers, and regulatory or reimbursement barriers could constrain broader access.
References
[1] Catalyst Pharmaceuticals. Firdapse prescribing information, 2018.
[2] EvaluatePharma, 2022. Global orphan drug market report.
[3] FDA.gov. Orphan Drug Designation and Market Exclusivity.
[4] GoodRx, 2023. Firdapse pricing insights.
